KEY TAKEAWAYS
- The study aimed to comprehensively evaluate the efficacy of Pola-BR for treating R/R DLBCL by synthesizing data from relevant randomized controlled trials.
- The primary endpoint is OS.
- The results will guide clinical decisions and guidelines, acknowledging limitations and suggesting future research for R/R DLBCL.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with high relapse rates and poor prognosis in patients with relapsed/refractory (R/R). Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) has shown promising efficacy and safety as a salvage therapy for R/R DLBCL.
Mohammadreza Eslami and the team aimed to evaluate the efficacy of Pola-BR for treating R/R DLBCL by analyzing data from relevant randomized controlled trials.
The protocol outlines the eligibility criteria, search strategy, study selection, data extraction, and analysis methods for the systematic review. It will include randomized controlled trials comparing Pola-BR with other treatments for R/R DLBCL.
The primary endpoint is overall survival (OS), while secondary endpoints include progression-free survival (PFS) and the incidence of adverse events. A comprehensive search will be conducted across databases such as Medline/PubMed, Cochrane Library, Web of Science, Scopus, EMBASE, ProQuest, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from January 2000 to April 2024.
The Cochrane Risk of Bias 1 tool will be used to assess potential bias. Data synthesis will employ fixed-effect or random-effects models, with subgroup and meta-regression analyses to explore heterogeneity. Publication bias and sensitivity analyses will also be conducted, and the GRADE approach will evaluate the certainty of the evidence.
This systematic review and meta-analysis protocol offers a thorough framework for assessing Pola-BR’s efficacy in treating R/R DLBCL. The findings will aid in clinical decision-making and guideline development, addressing the need for effective, tolerable treatments. The study will also acknowledge potential limitations and biases and discuss future research directions.
No funding was received.
Source: https://pubmed.ncbi.nlm.nih.gov/39088571/
Eslami M, Mehrabi M, Payandeh M, et al. (2024). “Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.” PLoS One. 2024;19(8):e0308247. Published 2024 Aug 1. doi:10.1371/journal.pone.0308247
